The immunosuppressive microenvironment of solid tumors renders adoptively transferred T cells hypofunctional. However, adenoviral delivery of immunostimulatory cytokines IL2 and TNFa can significantly improve the efficacy of adoptive T-cell therapy. Using ret transgenic mice that spontaneously develop skin malignant melanoma, we analyzed the mechanism of action of adenoviruses coding for IL2 and TNFa in combination with adoptive transfer of TCR-transgenic TRP-2-specific T cells. Following T-cell therapy and intratumoral virus injection, a significant increase in antigen-experienced, tumor-reactive PD-1 + CD8 + T cells was seen in both cutaneous lesions and in metastatic lymph nodes. A reverse correlation between tumor weight and the number of tumor-reactive PD-1 + tumor-infiltrating lymphocytes (TILs) was observed, suggesting that these T cells could target and kill tumor cells. It is interesting to note that, local expression of cytokines did not affect intratumoral levels of T-regulatory cells (Tregs), which had previously been associated with systemic IL2 therapy. Instead, Ad5-IL2 induced upregulation of IL2 receptor achain (CD25) on conventional CD4 + CD25 + Foxp3 À cells, indicating that these CD4 + T cells may contribute to CD8 + T-cell activation and/or homing. Signs of therapy-induced resistance were also observed as the expression of PD-L1 on tumor-infiltrating granulocytic myeloid-derived suppressor cells was upregulated as a reaction to PD-1 + TILs. Finally, beneficial ratios between tumorreactive PD-1 + CD8 + TILs and immunosuppressive cell subsets (Tregs and nitric oxide-producing myeloid-derived suppressor cells) were observed in primary and secondary tumor sites, indicating that local delivery of IL2 and TNFa coding adenoviruses can systemically modify the cellular composition of the tumor microenvironment in favor of adoptively transferred T cells.
Summary:
The immunosuppressive microenvironment of solid tumors renders adoptively transferred T cells hypofunctional. However, adenoviral delivery of immunostimulatory cytokines IL2 and TNFa can significantly improve the efficacy of adoptive T-cell therapy. Using ret transgenic mice that spontaneously develop skin malignant melanoma, we analyzed the mechanism of action of adenoviruses coding for IL2 and TNFa in combination with adoptive transfer of TCR-transgenic TRP-2-specific T cells. Following T-cell therapy and intratumoral virus injection, a significant increase in antigen-experienced, tumor-reactive PD-1 + CD8 + T cells was seen in both cutaneous lesions and in metastatic lymph nodes. A reverse correlation between tumor weight and the number of tumor-reactive PD-1 + tumor-infiltrating lymphocytes (TILs) was observed, suggesting that these T cells could target and kill tumor cells. It is interesting to note that, local expression of cytokines did not affect intratumoral levels of T-regulatory cells (Tregs), which had previously been associated with systemic IL2 therapy. Instead, Ad5-IL2 induced upregulation of IL2 receptor achain (CD25) on conventional CD4 + CD25 + Foxp3 À cells, indicating that these CD4 + T cells may contribute to CD8 + T-cell activation and/or homing. Signs of therapy-induced resistance were also observed as the expression of PD-L1 on tumor-infiltrating granulocytic myeloid-derived suppressor cells was upregulated as a reaction to PD-1 + TILs. Finally, beneficial ratios between tumorreactive PD-1 + CD8 + TILs and immunosuppressive cell subsets (Tregs and nitric oxide-producing myeloid-derived suppressor cells) were observed in primary and secondary tumor sites, indicating that local delivery of IL2 and TNFa coding adenoviruses can systemically modify the cellular composition of the tumor microenvironment in favor of adoptively transferred T cells. A doptive cell therapy (ACT) using genetically modified T cells has shown exceptional efficacy in the treatment of CD19 + hematological cancers. 1 However, far less impressive results have been achieved in the treatment of solid tumors due to local immunosuppression and peripheral tolerance, rendering tumor-infiltrating T cells (TILs) hypofunctional. This has been best demonstrated in metastatic melanoma, where ACT can result in high response rates but only when coupled with preconditioning that counteracts immunosuppression. [2] [3] [4] [5] Unlike in the case of "liquid tumor" environment of hematological cancers, antitumor T cells must successfully migrate to and infiltrate solid tumors with different physical and immunosuppressive barriers that can also suppress TIL activity. 6 We have previously shown that adenovirus (Ad) infection can enhance the efficacy of ACT 7, 8 and that intratumoral administration of recombinant cytokines can result in a favorable alteration of tumor microenvironment. 9 To combine the benefits of both approaches, we studied whether cytokine-armed adenoviruses could enhance the efficacy of ACT in a mouse melanoma model. Consequently, notable antitumor efficacy was achieved with the combination of adoptively transferred T cells and weekly injections of Ad5-CMV-mIL2 or Ad5-CMVmTNFa. 10 Moreover, when both these viruses were combined with T-cell transfer, tumor growth was significantly reduced compared with single-agent therapies 10 indicating that the double cytokine approach could be an effective way to enable T-cell therapy in solid tumors. However, the caveat of these studies was the artificial nature of the subcutaneous transplantable model featuring an immunogenic chicken peptide as a model epitope. In contrast, human melanoma occurs spontaneously and lacks avian antigens.
The ret transgenic mouse model has been described to resemble human melanoma with respect to histopathology and clinical development. 11, 12 Tumor-bearing mice developed metastases in lymph nodes (LN) and some distant organs such as the lungs, liver, brain, and bone marrow. 12 In addition, as observed in melanoma patients, tumorbearing mice develop a profound immunosuppression characterized by accumulation of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg). [13] [14] [15] [16] In this study, we analyzed the mechanism and systemic immunologic effect of the combination of Ad5-CMV-mIL2 and Ad5-CMV-mTNFa both on tumor-infiltrating T cells and on immunosuppressive cell subsets (MDSC and Treg) in the context of spontaneous metastatic malignant melanoma. Using the ret transgenic mouse model, we showed that the combination of IL2-expressing and TNFaexpressing adenoviruses can systematically activate tumor-infiltrating lymphocytes (TILs) and alter the immune cell composition of these primary and secondary tumors in favor of antitumor T-cell responses. Taken together, these preclinical results support the use of intratumorally administrated cytokine-coding adenoviruses in combination with adoptive T-cell therapy.
MATERIALS AND METHODS

Adenoviruses
The replication-deficient adenoviruses Ad5-CMVmIL2 and Ad5-CMV-mTNFa have been described. 10 Briefly, viruses consist of a human adenovirus serotype 5 (Ad5) nucleic acid backbone inserted with a transgene coding for murine IL2 or TNFa under the cytomegalovirus (CMV) promoter.
Mice
Ret transgenic mice (C57BL/6 background) expressing human ret transgene in melanocytes under the control of mouse metallothionein I promoter enhancer were generously provided by Dr I. Nakashima (Chubu University, Aichi, Japan). Tyrosinase-related protein (TRP)-2 TCRtransgenic mice (CD57BL/6 background) with CD8 + T cells specific for the TRP-2 peptide (180-188) were kindly provided by Dr A. Hurwitz (NCI, Bethesda, MD). All mice were crossed and kept under specific pathogen-free conditions in the animal facility of German Cancer Research Center (Heidelberg, Germany). Experiments were done in accordance with government and institute guidelines and regulations. The general performance of mice was monitored daily. Spontaneous tumor development was assessed macroscopically.
Isolation and Activation of TRP-2-specific Cells for Adoptive Transfer
For generation of TRP-2-specific T cells, spleens were collected from sixty 6-to 12-week-old TRP-2 mice and single-cell suspensions were prepared. Pooled splenocytes were treated with ammonium chloride (to lyse red blood cells), washed and cultured on 6-well plates or Petri dishes containing 1-mM TRP-2 (180-188) peptide SVYDFFVWL, and 20-U/mL murine IL2 (PeproTech, Rocky Hill, NJ) in 10% RPMI (at the concentration of 6.5 Â10 5 cells/mL). After 2 days of culture, the cells were centrifuged, washed, and prepared for adoptive transfer into tumor-bearing ret transgenic mice.
Treatment Regimen
After macroscopic cutaneous tumors had been formed, male and female ret transgenic mice were matched according to the tumor load. Mice were treated with intratumoral injections of 1 Â10 9 and 5 Â10 7 viral particles of adenovirus (in 50-mL PBS) on days 0 and 6, respectively. For the combination of Ad5-CMV-mIL2 and Ad5-CMVTNFa, 1:1 mixture was administered. On the first day of virus treatment, some mice also received adoptive transfer of 2 Â10
7 TRP-2 TCR-transgenic cells (in 200-mL PBS) intraperitoneally. Administration into intraperitoneal cavity was based on the observation that the total number and accumulation kinetics of adoptively transferred cells in preclinical mouse models is independent of injection route. 17 On day 12 posttransfer, mice were euthanized by cervical dislocation and tumors and LNs (pooled for each mouse) were collected for immunologic analyses. In addition, primary tumors were weighed as a surrogate parameter for efficacy as the developed tumors were flat and frequently located near or behind the eyes and nose, 12 making the traditional caliper measurement of tumors unfeasible.
Preparation of Single-Cell Suspensions From Tumor-bearing Mice
Fresh tumor and metastatic LN samples were collected in ice-cold PBS and stored on ice. Single-cell suspensions were prepared by smashing the tumors and LNs with a syringe plunger through a 100-mm cell strainer. Following lysis of red blood cells by ammonium chloride, cells were washed twice and stained for flow cytometry.
Antibodies and Reagents
The following rat anti-mouse directly conjugated monoclonal antibodies were used for the flow cytometry staining: CD3-PerCP, CD8-APC, CD4-PE-Cy7, CD25-APC-Cy7, Foxp3-FITC, TCR z-chain-PE, PD-1-BV421, CD45.2-PerCP, CD11b-APC-Cy7, Gr-1-PeCy7, Ly6C-APC, and PD-L1-BV421 (all from BD Biosciences, San Jose, CA). Production of intracellular nitric oxide (NO) was detected by 4,5-diaminofluorescein diacetate (DAF-2DA; from Cell Technology, Fremont, CA).
Flow Cytometry
Single-cell suspensions were stained with monoclonal antibodies for 30 minutes at 41C. For intracellular staining, samples were fixed for 45 minutes at 41C and permeabilized using the FoxP3 fixation/permeabilization kit (BD Biosciences). Acquisition was done by 6-and 7-color flow cytometry using FACSCanto II with FACSDiva software (both from BD Biosciences) with dead cell exclusion based on scatter profile. FlowJo software (Tree Star, Ashland, OR) was used to analyze 800,000 events (for LNs) or 1,000,000 events (for tumors). Fluorescence minus one control was included for all activation-related markers and gating was performed accordingly. Data were expressed as dot plots and histograms.
Statistical Analysis
Statistics was performed with GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA) using unpaired, 2-tailed Student t test to determine statistical significance between the control and therapy groups. Correlation between the 2 variables was calculated using Spearman correlation analysis. Differences were considered statistically significant when P-values were <0.05.
RESULTS
Total Levels of Tumor-infiltrating T Cells Following Triple Combination Therapy
To decipher the mechanism of action underlining the previously observed treatment efficacy of adenoviruses armed with murine cytokines TNFa and IL2, 10 we isolated splenocytes from TRP-2 TCR-transgenic mice and performed an adoptive transfer of 2 Â10 7 cells into ret transgenic mice with macroscopic cutaneous tumors expressing the target antigen TRP-2. 18 In addition, the mice were treated with intratumoral injections of adenovirus at days 0 and 6, using matching doses of either single viruses or a 1:1 mixture of both viruses. At day 12 after starting the treatments, primary melanomas from each mouse were pooled and weighed to determine the stage of tumor progression following therapy. The mean weight of these primary tumors was lower in treatment groups receiving intratumoral administration of TNFa-coding and IL2-coding adenoviruses, albeit statistical significance was not reached (Fig. 1A) . However, when groups were combined based on intratumoral treatments (with or without systemic ACT), skin melanomas were found to be significantly smaller in groups injected with TNFa/IL2 as compared with noninjected tumors (P < 0.05) (Fig. 1B) .
To evaluate tumor-infiltrating immune cell subsets and their functional status, primary skin tumors and metastatic LNs were collected from each mouse and stained for multicolor flow cytometry. The analysis of tumor-infiltrating T cells ( Fig. 2A) revealed that the combination of TNFacoding and IL2-coding adenoviruses increased the total amount of effector CD8 + TILs in primary cutaneous tumors as compared with untreated controls (P < 0.05) (Fig. 2B ). Moreover, a significant enhancement in CD8 + T-cell infiltration was observed in metastatic LN from mice treated with TNFa/IL2/T cells as compared with mice left untreated (P < 0.05) or treated with T cells only (P < 0.01) or with TNFa and T cells (P < 0.05) (Fig. 2C ). In contrast, whereas total levels of CD4 + T cells did not differ between groups in primary tumors (Fig. 2D ), a significant reduction in CD4
+ TILs was seen in metastatic LN from mice treated with TNFa/IL2/T cells as compared with untreated (P < 0.05), T-cell-treated (P < 0.01), and TNFa/T-celltreated mice (P < 0.05) (Fig. 2E ).
Infiltration of Tumor-reactive CD8 + T Cells in Primary Tumors and Metastatic Sites
Programmed cell death 1 (PD-1) is a membrane protein upregulated upon antigen recognition by T cells. 19 Despite its well-documented negative role in oncoimmunology, 20 PD-1-expressing TILs were recently identified as clonally expanded tumor-reactive T cells by Gros et al. 21 To gain further information on the tumor-infiltrating T-cell subsets, we analyzed the frequency of PD-1 + CD8 + TILs in mice subjected to different treatments (Fig. 3A) . Triple combination therapy significantly increased the levels of tumor-reactive PD-1 + CD8 + TILs in cutaneous lesions as compared with untreated mice and those treated with T cells only (both P < 0.05) (Fig. 3B) . It is interesting to note that, even more pronounced differences were observed in noninjected metastatic LNs, with TNFa/IL2/T-cell-treated mice having a significant increase in PD-1 + CD8 + T cells compared with mice left untreated (P < 0.01) or treated with either T cells alone (P < 0.01) or with T cells and single viruses (P < 0.05) (Fig. 3C) . Moreover, when a Spearman correlation analysis was performed, a statistically significant correlation between the weight of primary tumors and the frequency of tumor-infiltrating PD-1 + CD8
+ T cells was observed (P = 0.0015) (Fig. 3D ), suggesting that these T cells can recognize and kill their target tumor cells.
Analysis of CD4 + TIL Subsets Following Local IL2 Administration
As systemic, high-dose IL2 administration has been shown to increase the frequency of Tregs, 22 we evaluated whether this could be circumvented by administering the IL2 locally in the form of a viral vector. Flow cytometry analysis did not reveal any significant differences in the frequency of Foxp3 + CD25 + CD4 + Tregs in either primary tumors (Fig. 4A ) or in metastatic LNs (Fig. A , Supplemental Digital Content 1, http://links.lww.com/JIT/ A451). Similarly, the total levels of activated, conventional (non-Treg) CD4 + TILs were equal in all treatment groups ( Fig. 4B and Fig. B , Supplemental Digital Content 1, http:// links.lww.com/JIT/A451). However, intratumoral treatment with IL2-coding adenovirus upregulated the expression of CD25 on these conventional T cells (Figs. 4C, D) , which may be expected as CD25 represents the a-chain of IL2 receptor. 23 Similar expression changes were not observed on CD8 + TILs or on tumor-infiltrating Tregs (data not shown), suggesting that the effect was cell subtype specific.
Effect of Therapy on MDSCs
As MDSCs have been shown to play an important role in the suppression of antitumor immune responses, 15, 24 we wanted to decipher whether different MDSC populations were affected by the triple combination therapy. Analyzing the Gr-1 + CD11b + cells (Fig. 5A) , we found no significant differences in total MDSC levels in primary cutaneous tumors (Fig. 5B) , but a slight increase in MDSCs infiltrating the metastatic LNs following IL2/TNFa/T-cell combination therapy as compared with mice treated with T cells only (P < 0.05) or with TNFa and T cells (P < 0.05) (Fig. 5C) . However, as the total levels of MDSC in LNs were relatively low, these changes might not represent clinically relevant differences. Moreover, further analysis (Fig. 5D) without T cells (Figs. 5E, F) , but the lack of statistical significance prevented conclusive interpretations. Moreover, when we characterized the monocytic (M-MDSC) and granulocytic (G-MDSC) subsets in tumors and LNs, we found a slight polarization toward M-MDSCs in the cytokine-treated groups (Figs. A, 
Expression of PD-L1 in Melanoma Lesions Upon the Treatments
As we detected a significant increase in activated, tumor-reactive PD-1 + CD8 + TILs in primary tumors following triple combination therapy, we examined the expression levels of the corresponding ligand, PD-L1 (Fig. 6A) . Analysis of CD45 À cells in cutaneous tumors representing mostly melanoma cells revealed that the level of PD-L1 expression assessed by mean fluorescence intensity was not affected by cytokine-expressing viruses (Fig. 6B) . However, the triple combination treatment led to an upregulation of PD-L1 on tumor-infiltrating MDSCs when compared with T-cells-only group (P < 0.05) (Fig. 6C) . Further subset analysis indicated that these affected cells were G-MDSCs (Fig., Supplemental Digital Content 3, http://links.lww.com/JIT/A453). It is interesting to note that, we also observed a significant correlation between the frequency of PD-1 + CD8 + TILs and the mean PD-L1 expression on MDSCs (P = 0.0358) (Fig. 6D) , suggesting that tumor-infiltrating MDSCs may contribute to development of therapy-induced resistance.
Triple Combination Therapy Leads to a Favorable Modulation of the Tumor Microenvironment
As the amounts and functional status of tumorinfiltrating immune cell subsets can greatly affect the outcome of T-cell therapy, we assessed whether cytokineexpressing adenoviruses might alter the ratios between tumor-reactive TILs and immunosuppressive cells. Importantly, addition of IL2 and TNFa to the T-cell therapy regimen strongly increased the relative ratios of PD-1 +
CD8
+ T cells to NO-producing MDSC in primary tumors compared with untreated animals (P < 0.001) or mice treated with T cells only (P < 0.05) (Fig. 7A) . Similar observations were also made for metastatic LNs indicating markedly augmented PD-1 + CD8 + T cells/NO + MDSCs ratios in IL2/TNFa/T-cell-treated mice as compared with untreated mice (P < 0.01) and to group treated with both viruses (P < 0.05) (Fig. 7B) . In addition, the ratio between PD-1 + CD8 + TILs and Tregs in cutaneous melanomas was notably higher following triple combination treatment than in mice receiving T cells alone (P < 0.05) (Fig. 7C) . In metastatic LNs, the IL2/TNFa/T-cell treatment regimen induced an elevation of PD-1 + CD8 + TILs/Treg ratios as compared with groups of untreated animals (P < 0.05), treated with T cells alone (P < 0.05), and TNFa and T cells (P < 0.05) (Fig. 7D ). In conclusion, triple combination therapy can skew the immune cell balance of the tumor microenvironment in favor of tumor-reactive T cells and, more importantly, this effect can be seen both in the primary tumors (injected with viral vectors) as well as in secondary, noninjected tumor sites such as metastatic LN.
DISCUSSION
Several different preconditioning and postconditioning regimens have been used in adoptive T-cell therapies to improve their efficacy. [2] [3] [4] [5] One such approach has included a posttransfer administration of recombinant IL2 to boost the proliferation and persistence transferred of T cells. 25, 26 However, the short half-lives of recombinant proteins such as IL2 necessitate high systemic concentrations, which have been associated with toxicity. 3, 27, 28 Moreover, it seems almost counterintuitive to deliver systemically a molecule that has significant toxicities in nontarget organs, which limits the concentration that can be achieved at the target tissue, that is, the tumor.
The key advantage of adenovirus-vectored delivery is the continued local (intratumoral) expression of the therapeutic protein(s) coupled with the immunostimulatory properties of the virus through TLR/PAMP danger signaling. 29 A small number of preliminary human studies have been performed with nonreplicating adenoviruses coding for cytokines such as IL2, interferon-a (IFNa), and IFNg. [30] [31] [32] These trials have demonstrated that vectormediated cytokine delivery is a viable concept. Moreover, we have previously shown that intratumoral injections of IL2-coding and TNFa-coding adenoviruses lead to high local and low systemic levels of these cytokines and can greatly improve the treatment efficacy of adoptive T-cell transfer in melanoma mouse model. 10 To delineate the underlining mechanisms, we decided to perform a series of immunologic analyses in a clinically relevant ret transgenic mouse model of malignant melanoma 11, 12 to assess both local and systemic immune responses following intratumoral virus administration. On day 12 posttransfer, elevated levels of tumor-infiltrating CD8 + T cells were observed both in primary tumors and in metastatic LNs of mice treated with T-cell therapy and IL2/ Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
TNFa viruses (Figs. 2B, C) . Moreover, total levels of CD4 + TILs were decreased in metastatic LNs (Fig. 2E) , indicating that IL2/TNFa treatment favored homing and/or proliferation of CD8 + T cells over CD4 + T cells. Thus, an important finding was that local adenoviral delivery of IL2 and TNFa results in systemic immunologic gains. In addition, the functional analysis of conventional (non-Treg) CD4 + T cells revealed that expression of the early activation marker CD25 was upregulated in the tumors treated with Ad5-CMV-IL2 (Fig. 4D ). This suggests that CD4 + helper cells may have had a role in the induced antitumor response either by licensing dendritic cells 33, 34 or by promoting accumulation and differentiation of effector CD8 + T cells. 35, 36 As clinical data have shown, the total levels of CD8 + TILs alone might not predict treatment efficacy as T-cell functionality could be reduced due to Treg-mediated immunosuppression. [37] [38] [39] This was a special concern as IL2 administration has previously been associated with increased frequency of Tregs in cancer patients. 22, [40] [41] [42] [43] Thus, we analyzed the levels of tumor-infiltrating Tregs and to our surprise and delight, did not find statistically significant differences between the groups treated with IL2 and other groups (Fig. 4A) . The obvious contrast of these results to the published patient data indicate that local (intratumoral) IL2 delivery might not induce Treg expansion to such extent as systemic IL2, maybe because Treg proliferation takes place mainly in draining LNs. 44 Importantly, Treg levels in metastatic LNs remained unchanged ( The immune checkpoint molecule PD-1 is upregulated following TCR engagement and thus the expression is strongly linked to T-cell activation upon recognition of specific target antigen. 46, 47 The negative regulatory role of PD-1 in T-cell responses is due to the concomitant expression and subsequent interaction with corresponding ligand(s) on target cells, leading to impaired proliferation and exhausted state. 48, 49 However, a strong positive signal through CD28 or IL2 receptor may overcome inhibitory effects of PD-1 on T-cell proliferation, differentiation, and survival. 50, 51 Moreover, PD-1 + TILs, but not the negative counterparts, have been found to recognize and lyse their autologous tumor cell lines, suggesting that PD-1 expression accurately defines the broad repertoire of tumorreactive T cells in human melanoma tumors. 21 In line with these reports, we observed a significant increase in the frequency of antigen-experienced PD-1 + CD8 + T cells both in primary and secondary tumor sites following triple combination therapy (Figs. 3B, C) . A similar increase in the levels of CD8 + TILs recognizing tumor cells has previously been observed with mere adenoviral backbone (without therapeutic transgenes) when combined with ACT. 7, 8 Importantly, a negative correlation between the primary tumor weight and the frequency of PD-1 + CD8
+ TILs indicated that these T cells had been functional despite the expression of PD-1 (Fig. 2D) , possibly due to the strong exogenous IL2 stimulus that may help overcoming PD-L1-mediated inhibition. 51 Moreover, we did not observe any reduction in the level of TCR z-chain expression in PD-1 + CD8 + TILs, indicating that downstream TCR signaling was not affected by the expression of PD-1 (data not shown).
In addition to increased TIL levels, also therapyinduced resistance was observed as tumor-infiltrating MDSCs upregulated the expression of PD-L1 in response to tumor-reactive PD-1 + TILs (Fig. 6D) . As PD-L1 expression on CD45-negative cells (mostly tumor cells) remained unchanged (Fig. 6A) , these data suggested that myeloid cells could trigger a counterresponse to dampen the antitumor immunity induced by the cytokine-coding viruses. Similar posttreatment upregulation of PD-L1 in tumors treated with oncolytic adenovirus coding for GM-CSF was recently described in patients with several solid tumors 52 and is probably due to T-cell-derived IFNg secretion following recognition of the target antigen. 53, 54 Our results shed light on the possible counterresponsive mechanism to tumor-reactive CTLs and suggest that targeting these immunosuppressive myeloid populations either by checkpoint blockade or MDSC-inhibiting chemotherapy 13,14 may be a key to an effective immune response. Moreover, as baseline levels may significantly differ from therapy-induced levels of PD-L1, this adaptive myeloidderived upregulation of PD-L1 may explain why some patients with tumors showing no PD-L1 expression benefit from checkpoint inhibition. 55 A growing body of evidence suggests that MDSCs are central regulators of the immune response under different pathologic conditions and largely responsible for suppression of antitumor immunity due to different immunosuppressive mechanisms. 15 In our experiments, total levels of tumor-associated MDSCs were not increased by the cytokine combination treatment. However, the immunosuppressive pattern of MDSC subsets was found to be altered, as the expression of PD-L1 on G-MDSCs was upregulated following triple combination therapy, whereas Advanced solid tumors are infiltrated by cells of both myeloid and lymphoid lineages. This diverse repertoire of tumor-infiltrating immune cells can play a major role in determining the outcome of cancer immunotherapies by contributing to tumor destruction or therapy resistance. 56 Modulation of the phenotypic profile and functionality of these cells may prove to be essential especially in terms of ACTs, which have lacked sufficient efficacy in solid tumors without preconditioning and postconditioning regimens. 57 Flow cytometric analysis of cutaneous tumors treated with IL2-coding and TNFa-coding adenoviruses revealed immunomodulation in favor of antitumor T-cell responses, as we found increased ratios of PD-1 + CD8 + TILs to immunosuppressive immune cells (NO-producing MDSCs or Tregs) (Figs. 7A, C) . A similar elevation of effector cell/ suppressor cell ratios has been previously reported to be associated with a favorable disease outcome in multiple cancer types. [37] [38] [39] 58 Most importantly, we observed similar immunologic changes also in distant metastatic sites (LN) that were not subjected to injections (Figs. 7B, D) , suggesting that the altered cytokine/chemokine milieu of the injected primary tumor can affect different intratumoral and peritumoral immune cell subsets (such as dendritic cells, NK cells, and helper T cells 10 ), which can migrate in and out of the tumor bed and stimulate antitumor CD8 + T cells in LNs. 59 In addition, the lymphatic drainage from the injected primary tumor may contain elevated levels of either virally coded cytokines or other IL2-induced or TNFa-induced cytokines or growth factors, 60 leading to decrease in systemic tolerance. Taken together, the triple combination therapy may induce systemic host antitumor immune activity and thus enable effective cancer immunotherapy in metastasized cancers with poor prognosis.
In conclusion, triple combination therapy can skew the immune cell balance of the tumor microenvironment in favor of tumor-reactive T cells. Moreover, this effect can be seen both in the primary, injected tumors and in secondary, noninjected metastatic lesions. Further studies of immune repertoires infiltrating human tumors following immunomodulatory therapies would be useful for additional insights into both basic immunobiology and the mechanistic basis of efficacy or lack of efficacy of T-cell therapies in the treatment of solid tumors. However, our data provide a strong rationale for translation into human trials.
